Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.